多发性硬化急性加重期的管理。
Management of acute exacerbations in multiple sclerosis.
作者信息
Ontaneda Daniel, Rae-Grant Alex D
机构信息
Neurological Institute, Cleveland Clinic, Cleveland, Ohio, 44195 USA.
出版信息
Ann Indian Acad Neurol. 2009 Oct;12(4):264-72. doi: 10.4103/0972-2327.58283.
Abstract
A key component of multiple sclerosis is the occurrence of episodes of clinical worsening with either new symptoms or an increase in older symptoms over a few days or weeks. These are known as exacerbations of multiple sclerosis. In this review, we summarize the pathophysiology and treatment of exacerbations and describe how they are related to the overall management of this disease.
摘要
多发性硬化症的一个关键组成部分是在几天或几周内出现临床症状恶化的发作，伴有新症状或原有症状加重。这些被称为多发性硬化症的发作。在本综述中，我们总结了发作的病理生理学和治疗方法，并描述了它们与该疾病整体管理的关系。
相似文献
1
Management of acute exacerbations in multiple sclerosis.
Ann Indian Acad Neurol. 2009 Oct;12(4):264-72. doi: 10.4103/0972-2327.58283.
2
Self reported stressful life events and exacerbations in multiple sclerosis: prospective study.
BMJ. 2003 Sep 20;327(7416):646. doi: 10.1136/bmj.327.7416.646.
3
[Therapeutic indications for acute episodes of multiple sclerosis].
Rev Neurol (Paris). 2001 Sep;157(8-9 Pt 2):988-95.
4
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Cochrane Database Syst Rev. 2012 Dec 12;12:CD006921. doi: 10.1002/14651858.CD006921.pub3.
5
Acute Multiple Sclerosis Relapse.
Continuum (Minneap Minn). 2016 Jun;22(3):799-814. doi: 10.1212/CON.0000000000000330.
6
Practical management problems of chronic obstructive pulmonary disease in the elderly: acute exacerbations.
Curr Opin Pulm Med. 2011 Dec;17 Suppl 1:S49-54. doi: 10.1097/01.mcp.0000410748.28582.22.
7
[Influence of acute aggravations on the development of long-term handicap in relapsing remitting multiple sclerosis: a clinical study in 99 patients].
Rev Neurol (Paris). 2007 Jan;163(1):72-81. doi: 10.1016/s0035-3787(07)90357-4.
8
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Cochrane Database Syst Rev. 2009 Jul 8(3):CD006921. doi: 10.1002/14651858.CD006921.pub2.
9
Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis.
Neurol Ther. 2021 Jun;10(1):149-167. doi: 10.1007/s40120-020-00219-y. Epub 2020 Nov 10.
10
Repository corticotropin injection in multiple sclerosis: an update.
Neurodegener Dis Manag. 2018 Aug;8(4):217-225. doi: 10.2217/nmt-2018-0008. Epub 2018 Jun 5.
引用本文的文献
1
Potential Application of Plant-Derived Compounds in Multiple Sclerosis Management.
Nutrients. 2024 Sep 5;16(17):2996. doi: 10.3390/nu16172996.
2
Patterns of multiple sclerosis presentation to the emergency department.
Front Neurol. 2024 Apr 26;15:1395822. doi: 10.3389/fneur.2024.1395822. eCollection 2024.
3
Tumefactive multiple sclerosis.
Proc (Bayl Univ Med Cent). 2024 Feb 8;37(2):344-347. doi: 10.1080/08998280.2023.2289301. eCollection 2024.
4
Multiple Sclerosis-A Demyelinating Disorder and Its Dental Considerations-A Literature Review with Own Case Report.
Brain Sci. 2023 Jun 29;13(7):1009. doi: 10.3390/brainsci13071009.
5
Current Updates on the Diagnosis and Management of Multiple Sclerosis for the General Neurologist.
J Clin Neurol. 2023 May;19(3):217-229. doi: 10.3988/jcn.2022.0208.
6
Immunomodulatory Aspects of Therapeutic Plasma Exchange in Neurological Disorders-A Pilot Study.
Int J Mol Sci. 2023 Mar 31;24(7):6552. doi: 10.3390/ijms24076552.
7
Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses.
J Neuroinflammation. 2022 Sep 7;19(1):220. doi: 10.1186/s12974-022-02583-y.
8
Predictors of progression from a first demyelinating event to clinically definite multiple sclerosis.
Brain Commun. 2022 Jul 9;4(4):fcac181. doi: 10.1093/braincomms/fcac181. eCollection 2022.
9
Current Utilization and Research Status of Traditional East Asian Herbal Medicine Treatment for Multiple Sclerosis: A Scoping Review.
Front Neurol. 2021 Oct 18;12:710769. doi: 10.3389/fneur.2021.710769. eCollection 2021.
10
Amnion-Derived Multipotent Progenitor Cells Suppress Experimental Optic Neuritis and Myelitis.
Neurotherapeutics. 2021 Jan;18(1):448-459. doi: 10.1007/s13311-020-00949-9. Epub 2020 Oct 16.
本文引用的文献
1
Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
J Clin Neuromuscul Dis. 2008 Dec;10(2):52-5. doi: 10.1097/CND.0b013e31818b2aef.
2
Multiple sclerosis.
Lancet. 2008 Oct 25;372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7.
3
EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.
Eur J Neurol. 2008 Sep;15(9):893-908. doi: 10.1111/j.1468-1331.2008.02246.x.
4
B cells and multiple sclerosis.
Lancet Neurol. 2008 Sep;7(9):852-8. doi: 10.1016/S1474-4422(08)70192-3.
5
Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
Eur J Neurol. 2008 Jul;15(7):677-80. doi: 10.1111/j.1468-1331.2008.02146.x. Epub 2008 May 6.
6
Corticosteroids for multiple sclerosis: I. Application for treating exacerbations.
Neurotherapeutics. 2007 Oct;4(4):618-26. doi: 10.1016/j.nurt.2007.07.008.
7
Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis.
J Neurol. 2007 Sep;254(9):1288-9. doi: 10.1007/s00415-006-0497-0. Epub 2007 Aug 16.
8
Natalizumab for multiple sclerosis.
N Engl J Med. 2007 Jun 21;356(25):2622-9. doi: 10.1056/NEJMct071462.
9
Myelin regeneration in demyelinating disorders: new developments in biology and clinical pathology.
Curr Opin Neurol. 2007 Jun;20(3):294-8. doi: 10.1097/WCO.0b013e32813aee7f.
10
The incomplete nature of multiple sclerosis relapse resolution.
J Neurol Sci. 2007 May 15;256 Suppl 1:S14-8. doi: 10.1016/j.jns.2007.01.062. Epub 2007 Mar 2.
Zotero 插件